Quantcast
Last updated on April 18, 2014 at 8:42 EDT

Latest Heavy metal Stories

2013-11-26 08:26:56

CARLSBAD, Calif., Nov. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-GSK3(Rx) and earned a $3 million milestone payment from GlaxoSmithKline (GSK). ISIS-GSK3(Rx )is designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3(Rx) to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further...

2013-11-25 08:26:31

CARLSBAD, Calif., Nov. 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 8:25 a.m. ET in Boston, MA. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2013-11-22 08:23:05

CARLSBAD, Calif., Nov. 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). In addition, a 12 mg dose will be included in an open-label extension study for those children who have completed dosing in previous studies. The addition of the 12 mg cohort will allow for the investigation of this dose in support of the...

2013-11-15 08:26:58

CARLSBAD, Calif., Nov. 15, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation of ISIS-GSK4(Rx )as a development candidate. ISIS-GSK4(Rx) is an antisense drug designed to treat an undisclosed ocular disease. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) "Our collaboration with GlaxoSmithKline has been very productive resulting...

2013-11-06 23:00:14

Finnish metal star creates mobile presence with DIY app builder at appsbar.com Deerfield Beach, FL (PRWEB) November 06, 2013 Alexi Laiho has earned appsbar’s App of the Day award as an example of how independent artists and musicians are utilizing the no-cost DIY app building tool at appsbar.com to create dynamic, customized mobile apps. Laiho is well-known on the Finnish metal scene as the lead guitarist and vocalist of Children of Bodom. His mobile app chronicles his career through...

2013-11-05 08:35:12

-Improved 2013 financial guidance CARLSBAD, Calif., Nov. 5, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $22.7 million and $23.5 million for the three and nine months ended September 30, 2013, respectively, compared to a pro forma NOL of $26.0 million and $36.0 million for the same periods in 2012. On a GAAP basis, Isis reported a loss from operations of $25.5 million and $31.8 million for the three and nine months...

2013-10-30 08:25:02

ANDalyze and Hach expand the availability of DNAzyme testing technology for lead, copper, mercury, cadmium, zinc and uranium for drinking water, in a field portable product. CHAMPAIGN, Ill., Oct. 30, 2013 /PRNewswire/ -- ANDalyze has signed Hach as an authorized distributor for the ANDalyze's product line. Hach, a world leader in providing water quality testing instruments, will distribute the ANDalyze DNAzyme-based heavy metal testing products through its sales channels. Hach will...

2013-10-29 08:31:28

CARLSBAD, Calif., Oct. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Third Quarter 2013 Financial Results and Highlights Conference Call When: Tuesday, November 5, 2013 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How:...

2013-10-21 08:28:28

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced it has secured $5 million in a Series A funding round led by multiple private capital, high net-worth investors from Canada, Japan and the United States. (Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO) The Series A funding, which comprised more than 90% of the Series Seed investors, will enable...

2013-10-16 08:26:49

CARLSBAD, Calif., Oct. 16, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPK(Rx) to treat myotonic dystrophy type I (DM1). (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) "We are very pleased with the successes we are having in our alliance with Biogen Idec. The progress we have made is evidenced in our spinal...


Latest Heavy metal Reference Libraries

Brilliant Emerald, Somatochlora metallica
2013-07-30 14:54:37

The brilliant emerald (Somatochlora metallica) is a species of dragonfly that can be found in northern areas of Eurasia. Its range includes Austria, Belgium, Croatia, Denmark, France, Germany, Norway, Serbia, Sweden, and the United Kingdom, among many other areas. This species prefers to reside near still and slow-moving water sources like rivers, canals, ponds, and moorland lakes. It is common in most areas of its range, but its total population number and population trend is unknown. It is...

More Articles (1 articles) »